The FDA closed comments in mid-October on its August 2026 discussion paper about generative AI in medical devices, receiving more than 500 submissions. The paper floats evaluating such devices with a framework modeled on physician credentialing and puts heavy emphasis on monitoring after a product is on the market. The agency plans to use the feedback to develop guidance.<\/p>\n
Industry groups including AdvaMed, MDMA and GE HealthCare argue for building on the existing framework instead of creating a new one, and for broadening predetermined change control plans, which they call potentially too restrictive for generative AI. Physician and patient groups ask for stronger postmarket monitoring and safeguards against faulty advice from consumer chatbots, while hospital and provider groups argue that developers, not clinicians, should carry responsibility for safety and performance.<\/p>\n
Why it matters:<\/strong> whatever the FDA settles on will shape how AI features in anesthesia, infusion and monitoring equipment are cleared, updated and supervised after sale.<\/p>\n